European Commission Approves Obicetrapib as First-in-Class LDL-C Therapy
NAMS is trading near its 52-week low of $21.02 (8.6% above the low).
Summary
The European Commission granted marketing authorization for Ubeslo (obicetrapib 10 mg monotherapy) and Evlarco (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination), marking the first global regulatory approval of obicetrapib. The authorizations apply across all EU Member States, Iceland, Liechtenstein, and Norway, for primary hypercholesterolaemia (HeFH/non-familial) or mixed dyslipidaemia. This follows the CHMP positive opinion in July and is supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials showing LDL-C reductions up to 40% (monotherapy) and 50% (combination) with placebo-like tolerability. Menarini holds exclusive European commercialization rights and is responsible for regulatory interactions and commercialization activities in the region, while NewAmsterdam is entitled to tiered double-digit royalties ranging from low double-digits to mid-twenties on net sales plus up to €833 million in milestones. The EC approval triggers milestone payments in the mid-teens of millions of euros to NewAmsterdam under its Menarini licensing agreement. The EC requires a post-authorization efficacy study mandating submission of final PREVAIL trial results, as well as customary post-approval safety monitoring, pharmacovigilance activities, and risk-minimization measures. The approval validates the drug's commercial pathway in Europe and de-risks the broader obicetrapib franchise ahead of the PREVAIL cardiovascular outcomes trial readout, a placebo-controlled, double-blind, randomized trial evaluating obicetrapib monotherapy as adjunct to maximally tolerated lipid-lowering therapies to potentially enhance low-density lipoprotein cholesterol lowering in patients with atherosclerotic cardiovascular disease and/or HeFH.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The EC approval triggers milestone payments in the mid-teens of millions of euros to NewAmsterdam under its Menarini licensing agreement.
- Approved Products — Ubeslo is obicetrapib 10 mg monotherapy; Evlarco is 10 mg obicetrapib plus 10 mg ezetimibe. Approved for primary hypercholesterolaemia (HeFH/non-familial) or mixed dyslipidaemia.
- Territory — Authorizations apply across all EU Member States, Iceland, Liechtenstein, and Norway.
- Post-Authorization Requirements — EC requires post-authorization efficacy study, mandating submission of final PREVAIL trial results. EC authorization requires customary post-approval safety monitoring, pharmacovigilance activities, and risk-minimization measures.
- Commercialization — Menarini is responsible for regulatory interactions and commercialization activities in the region. Tiered double-digit royalties range from low double-digits to mid-twenties on net sales.
- PREVAIL Trial — PREVAIL trial is placebo-controlled, double-blind, randomized, evaluating obicetrapib monotherapy as adjunct to maximally tolerated lipid-lowering therapies. PREVAIL trial aims to potentially enhance low-density lipoprotein cholesterol lowering in patients with atherosclerotic cardiovascular disease and/or HeFH.
All 9 details
- Ubeslo is obicetrapib 10 mg monotherapy; Evlarco is 10 mg obicetrapib plus 10 mg ezetimibe.
- Approved for primary hypercholesterolaemia (HeFH/non-familial) or mixed dyslipidaemia.
- Authorizations apply across all EU Member States, Iceland, Liechtenstein, and Norway.
- EC requires post-authorization efficacy study, mandating submission of final PREVAIL trial results.
- Menarini is responsible for regulatory interactions and commercialization activities in the region.
- Tiered double-digit royalties range from low double-digits to mid-twenties on net sales.
- EC authorization requires customary post-approval safety monitoring, pharmacovigilance activities, and risk-minimization measures.
- PREVAIL trial is placebo-controlled, double-blind, randomized, evaluating obicetrapib monotherapy as adjunct to maximally tolerated lipid-lowering therapies.
- PREVAIL trial aims to potentially enhance low-density lipoprotein cholesterol lowering in patients with atherosclerotic cardiovascular disease and/or HeFH.
At the time of this announcement, NAMS was trading at $22.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $21.02 to $42.21. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.